On the 26th, the US FDA = Food and Drug Administration held a committee of external experts to verify the efficacy and safety of the new coronavirus vaccine of pharmaceutical giant Johnson & Johnson, and the committee said, "The benefits of vaccination are risks. I have summarized the conclusion that "exceeds."
If the FDA decides to permit emergency use, it will be the third type in the United States.
On the 26th, the FDA held a committee to hear from outside experts about the new coronavirus vaccine developed by Johnson & Johnson that requires only one vaccination.
After reviewing the efficacy and safety data in detail, the committee voted, saying, "On scientific grounds, the benefits of vaccination of people over the age of 18 outweigh the risks." The conclusion was summarized by a large number of supporters.
In response, the FDA is expected to promptly decide on an emergency use permit in the future.
With permission for emergency use, it will be the third vaccine in the United States after Pfizer and Moderna vaccines.
While the Pfizer and Moderna vaccines require two doses, this vaccine only requires one dose and can be stored in the refrigerator at temperatures of 2 to 8 degrees Celsius for at least 3 months, accelerating the pace of vaccination. Is expected.
Johnson & Johnson says it will supply 100 million doses by the end of June, based on a contract with the US government, as soon as an emergency use permit is decided.